Bryan Hanson

Solventum is an approximately $8+ billion revenue company providing a broad portfolio of healthcare products: MedSurg (wound care dressings, medical tapes — including the iconic Tegaderm and Micropore brands, sterilization products, skin preparation), Dental Solutions (dental composites, adhesives, impression materials, orthodontic products), Health Information Systems (coding and classification software for healthcare providers), and Purification & Filtration (biopharmaceutical filtration, food safety testing). As a newly independent company, Solventum faces the challenge of establishing standalone operations, building its own corporate infrastructure, and demonstrating that separation from 3M's diversified conglomerate creates value. The healthcare business was long considered one of 3M's most attractive divisions — strong brands, recurring consumable revenue, and exposure to structural healthcare spending growth — but its growth had been constrained by 3M's broader challenges. 3M retained a 19.9% stake post-spin and Solventum inherited certain legacy liabilities. The company must now invest in innovation and commercial capabilities independently while optimizing its cost structure. Key stock drivers include organic revenue growth, operating margin expansion, new product launches, medical procedure volumes, dental market recovery, health IT adoption, separation execution, and the competitive dynamics against Johnson & Johnson, Mölnlycke, and other medical device companies.